177 related articles for article (PubMed ID: 32333643)
1. IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.
Rodriguez EF; De Marchi F; Lokhandwala PM; Belchis D; Xian R; Gocke CD; Eshleman JR; Illei P; Li MT
Cancer Med; 2020 Jun; 9(12):4386-4394. PubMed ID: 32333643
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 Mutations in Colorectal Cancers.
Huang J; Tseng LH; Parini V; Lokhandwala PM; Pallavajjala A; Rodriguez E; Xian R; Chen L; Gocke CD; Eshleman JR; Lin MT
Am J Clin Pathol; 2021 Oct; 156(5):777-786. PubMed ID: 33929516
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
Toth LN; de Abreu FB; Tafe LJ
Hum Pathol; 2018 Aug; 78():138-143. PubMed ID: 29723602
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
7. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
8. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
Hartman DJ; Binion D; Regueiro M; Schraut W; Bahary N; Sun W; Nikiforova M; Pai RK
Am J Surg Pathol; 2014 Aug; 38(8):1147-56. PubMed ID: 25029120
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.
Chen S; Zhu H; Jin M; Yuan H; Liu Z; Li J; Zhang X; Meng L; Li T; Diao Y; Gao H; Hong C; Zhu X; Zheng J; Li F; Niu Y; Ma T; Li X
Cancer Med; 2022 Nov; 11(22):4122-4133. PubMed ID: 35526267
[TBL] [Abstract][Full Text] [Related]
13. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
[TBL] [Abstract][Full Text] [Related]
14. Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies.
Shen E; Xiu J; Bentley R; López GY; Walsh KM
Clin Lung Cancer; 2020 Nov; 21(6):e523-e527. PubMed ID: 32414627
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
17. Next generation sequencing in lung cancer: An initial experience from India.
Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
[TBL] [Abstract][Full Text] [Related]
18. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
[TBL] [Abstract][Full Text] [Related]
19. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
20. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.
Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA
Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
